WoundReference improves clinical decisions
 Choose the role that best describes you
Baumgart DC, Wiedenmann B, Dignass AU, et al.
Inflammatory bowel diseases. Date of publication 2004 Jul 1;volume 10(4):421-4.
1. Inflamm Bowel Dis. 2004 Jul;10(4):421-4. Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitis. Baumgart DC(1), Wiedenmann B, Dignass AU. Author information: (1)Department of Medicine, Charité Medical Center-Virchow Hospital, Medical School of the Humboldt-University of Berlin, D-13344 Berlin, Germany. We describe two male patients with ulcerative colitis and refractory pyoderma gangrenosum including periorbital phlegmona in one case. Both patients were successfully managed with low dose oral tacrolimus (0.1 mg/kg bodyweight per day). Serum trough levels were closely monitored and maintained between 4 and 6 ng/mL. A rapid response was noted in both cases. Complete non-scarring skin restitution without side effects was accomplished in both cases. Low dose oral tacrolimus provides a valuable alternative treatment option for IBD patients with refractory pyoderma gangrenosum. PMID: 15475751 [Indexed for MEDLINE]
Appears in following Topics:
Pyoderma Gangrenosum - Treatment